T. Rowe Price (APGE) discloses 10.29M shares, 16.8% stake in Apogee

Rhea-AI Filing Summary

T. Rowe Price Investment Management, Inc. reports beneficial ownership of 10,291,220 shares of Apogee Therapeutics Inc. common stock, equal to 16.8% of the class as reported. The filing shows sole voting power over 9,762,311 shares and sole dispositive power over 10,291,220 shares. The T. Rowe Price Capital Appreciation Fund is disclosed with an interest of 5,295,932 shares (9.7%). The filing is signed and dated by an authorized officer.

Key Figures

Amount beneficially owned: 10,291,220 shares Percent of class: 16.8% Sole voting power: 9,762,311 shares +3 more

6 metrics

Amount beneficially owned 10,291,220 shares Amount beneficially owned reported on Schedule 13G/A

Percent of class 16.8% Percent of class reported on Schedule 13G/A

Sole voting power 9,762,311 shares Sole power to vote as reported

Sole dispositive power 10,291,220 shares Sole power to dispose as reported

T. Rowe Price Capital Appreciation Fund interest 5,295,932 shares Fund holding disclosed representing 9.7% of class

Filing date / signature date 04/08/2026 Signature date on the amendment

Key Terms

beneficially owned, sole voting power, sole dispositive power, Schedule 13G/A

4 terms

beneficially owned regulatory

"Amount beneficially owned: 10291220"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

sole voting power regulatory

"Sole Voting Power 9,762,311.00"

Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.

sole dispositive power regulatory

"Sole Dispositive Power 10,291,220.00"

Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

Schedule 13G/A regulatory

"(Amendment No. 1 ) APOGEE THERAPEUTICS INC"

A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/08/2026 - 03:26 PM Learn about SEC filing dates

FAQ

What stake does T. Rowe Price (APGE) report owning?

T. Rowe Price Investment Management reports beneficial ownership of 10,291,220 shares, representing 16.8% of Apogee Therapeutics common stock. This figure is the amount listed under "Amount beneficially owned" in the Schedule 13G/A.

How much voting power does T. Rowe Price hold in APGE?

The filing lists sole voting power for 9,762,311 shares. Shared voting power is reported as 0, indicating exclusive voting authority over that portion of the shares reported.

What portion of the stake is linked to T. Rowe Price Capital Appreciation Fund?

The Schedule 13G/A discloses that the T. Rowe Price Capital Appreciation Fund holds 5,295,932 shares, equal to 9.7% of the class, as part of the holdings managed by T. Rowe Price Investment Management.

Does T. Rowe Price claim direct beneficial ownership of APGE shares?

The filing expressly states that T. Rowe Price Investment Management "does not serve as custodian" and "declares and affirms" that the filing should not be construed as admission of beneficial ownership. Clients retain ultimate power to receive proceeds/dividends.

Which account and address are listed for the filer in the Schedule 13G/A?

The filer is listed as T. Rowe Price Investment Management, Inc. with principal office at 1307 Point Street, Baltimore, MD 21231. The issuer address is shown as 221 Crescent St., Building 17, Suite 102B, MA 02453.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

APOGEE THERAPEUTICS INC

(Name of Issuer)

COMMON STOCK

(Title of Class of Securities)

03770N101

(CUSIP Number)

03/31/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 03770N101

1

Names of Reporting Persons

T. Rowe Price Investment Management, Inc.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

MARYLAND

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 9,762,311.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 10,291,220.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

10,291,220.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

16.8 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

Item 1.
(a)	Name of issuer: APOGEE THERAPEUTICS INC
(b)	Address of issuer's principal executive offices: 221 CRESCENT ST., BUILDING 17, SUITE 102B, WALTHAM, MA, 02453
Item 2.
(a)	Name of person filing: T. Rowe Price Investment Management, Inc.
(b)	Address or principal business office or, if none, residence: 1307 Point Street, Baltimore, MD 21231
(c)	Citizenship: Maryland
(d)	Title of class of securities: COMMON STOCK
(e)	CUSIP No.:
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 10291220
(b)	Percent of class: 16.8 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 9762311
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 10291220
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. Ownership of More than Five Percent on Behalf of Another Person (1) Price Investment Management does not serve as custodian of the assets of any of its clients; accordingly, in each instance only the client or the client's custodian or trustee bank has the right to receive dividends paid with respect to, and proceeds from the sale of, such securities. The ultimate power to direct the receipt of dividends paid with respect to, and the proceeds from the sale of, such securities, is vested in the individual and institutional clients which Price Investment Management serves as investment adviser. Any and all discretionary authority which has been delegated to Price Investment Management may be revoked in whole or in part at any time. Except as may be indicated if this is a joint filing with one of the registered investment companies sponsored by Price Investment Management which it also serves as investment adviser ("T. Rowe Price Funds"), not more than 5% of the class of such securities is owned by any one client subject to the investment advice of Price Investment Management. (2) [T. ROWE PRICE CAPITAL APPRECIATION FUND ]: T. ROWE PRICE CAPITAL APPRECIATION FUND, of which T. Rowe Price Investment Management, Inc. is the investment adviser, holds the securities reported herein in their investment portfolio managed by T. Rowe Price Investment Management, Inc. and such funds have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities that they hold. T. ROWE PRICE CAPITAL APPRECIATION FUND has an interest in 5,295,932 of the class reported herein representing 9.7% of the class.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. T. Rowe Price Investment Management, Inc. hereby declares and affirms that the filing of Schedule 13G shall not be construed as an admission that Price Investment Management is the beneficial owner of the securities referred to, which beneficial ownership is expressly denied.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

T. Rowe Price Investment Management, Inc.

Signature:	Ellen York
Name/Title:	Vice President
Date:	04/08/2026